Shire Regenerative Medicine Initiates Phase 3 Study Of ABH001 For Patients With Epidermolysis Bullosa

Shire plc (LSE: SHP, NASDAQ: SHPG), have announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]� � "People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news